Ophthalmic compositions with omega-3 fatty acids
A technology of fatty acids and mixtures, applied in the field of ophthalmic compositions, can solve problems such as patient dissatisfaction, patient discomfort, and vision obstruction
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0070] A sterile aqueous solution of polyacrylic acid polymer is mixed with a sterile filtered solution of a mixture of omega-3 fatty acids, preservatives, isotonicity agents and chelating agents. After careful and thorough mixing of the starting materials, sterile filtered caustic soda solution was added to initiate gel formation, which was further stirred until it was homogenized. Alternatively, a mixture of omega-3 fatty acids can be first dissolved or suspended in a small amount of mineral oil and added to the polyacrylic acid polymer solution. The resulting suspension is then routinely decanted or drained under aseptic conditions.
[0071] Gel suspensions are well accepted by patients because they do not have the undesirable properties of known ointments when instilled, and are not oily. Furthermore, stability studies have demonstrated that the gel has a relatively long shelf life without any change in its physical properties. In particular, the mixture of omega-3 fatty...
Embodiment 2
[0084] The carrier formulations of the invention comprising a mixture of omega-3 fatty acids and jojoba wax esters are described in Table 3.
[0085] Table 3. Omega-3 / jojoba suspension formulations
[0086]
Embodiment 3
[0088] The carrier formulations of the invention comprising mixtures of omega-3 fatty acids and phospholipids are described in Table 4.
[0089] Table 4. Omega-3 / phospholipid suspension formulations
[0090]
[0091] To determine the tear thinning properties of Example 1, 30 mL of the composition was mixed with 10 mL of simulated tear fluid. As noted, it is believed that the thinning properties of the carrier formulation are primarily driven by the difference in ionic strength between the carrier formulation having a relatively low ionic strength and the tear fluid represented by the simulated tear fluid having a relatively high ionic strength. When the carrier formulation is administered to the eye in the form of eye drops, the percentage increase in the ionic strength of the carrier-tear mixture causes the carrier formulation to dilute. The concentration of lightly cross-linked carboxypolymer, the calculated ionic strength of the example (vehicle) formulations, and the p...
PUM
| Property | Measurement | Unit |
|---|---|---|
| yield strength | aaaaa | aaaaa |
| yield strength | aaaaa | aaaaa |
| yield strength | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 